PTCy + Sirolimus/VIC-1911 as GVHD Prophylaxis in Myeloablative PBSC Transplantation
Status:
Not yet recruiting
Trial end date:
2028-03-31
Target enrollment:
Participant gender:
Summary
This is a single-arm, phase I/II, study of PTCy/sirolimus plus VIC-1911 to prevent GVHD and
relapse after Allogeneic Hematopoietic Cell Transplantation (alloHCT).